Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the completion of the Investigational Medicinal Product Dossier ("IMPD") for BNT23001, the Company's lead proprietary sublingual cladribine oral dissolvable film (ODF) product candidate for the treatment of relapsing forms of multiple sclerosis (MS). Completion of the IMPD represents a significant regulatory milestone and advances BioNxt's lead development program toward its planned first human bioequivalence study.

VANCOUVER, BC / ACCESS Newswire / August 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to announce that it has closed its previously announced extension of unsecured convertible debentures (the "Debentures"), as initially disclosed in its news releases dated June 10 and 23, 2026. The Company amended the terms of the Debentures in the principal amounts of $425,000, $285,000, $1,400,000, $865,000, $1,600,000, and $900,000, bearing interest at a rate of 8% per annum to extend the maturity dates of the Debentures by one year to November 12, 2027, November 29, 2027, December 19, 2027, January 14, 2028, February 28, 2028, and March 14, 2028, respectively.

VANCOUVER, BC / ACCESS Newswire / August 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the completion of the Investigational Medicinal Product Dossier ("IMPD") for BNT23001, the Company's lead proprietary sublingual cladribine oral dissolvable film (ODF) product candidate for the treatment of relapsing forms of multiple sclerosis (MS). Completion of the IMPD represents a significant regulatory milestone and advances BioNxt's lead development program toward its planned first human bioequivalence study.

VANCOUVER, BC / ACCESS Newswire / August 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus and Semaglutide, while strengthening the intellectual property portfolio supporting its platform and preparing for the next phase of clinical and commercial development.

VANCOUVER, BC / ACCESS Newswire / August 4, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus and Semaglutide, while strengthening the intellectual property portfolio supporting its platform and preparing for the next phase of clinical and commercial development.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / July 31, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces that it has granted an aggregate of 750,000 stock options ("Options") pursuant to the Company's stock option plan (the "Option Plan") to certain insiders, consultants and an employee of the Company, each Option entitling the holder thereof to acquire one common share of the Company (a "Common Share") at an exercise price of $0.33 for a period of three years. All such Options vested immediately.